A phase I and pharmacokinetic study of oral 3-aminopyridine-2- carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: A California Cancer Consortium Study

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 3, 2012, Pages 835-843

  Chao, Joseph ^a   Synold, Timothy W ^a   Morgan, Robert J ^a   Kunos, Charles ^b   Longmate, Jeff ^a   Lenz, Heinz Josef ^c   Lim, Dean ^a   Shibata, Stephen ^a   Chung, Vincent ^a   Stoller, Ronald G ^d   Belani, Chandra P ^e   Gandara, David R ^f   McNamara, Mark ^c   Gitlitz, Barbara J ^c   Lau, Derick H ^f   Ramalingam, Suresh S ^g   Davies, Angela ^h   Espinoza Delgado, Igor ⁱ   Newman, Edward M ^a   Yen, Yun ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e PENN STATE CANCER INSTITUTE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g EMORY UNIVERSITY   (United States)

^h OSI Pharmaceuticals   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

3 AP; Oral triapine; Phase I trial; Ribonucleotide reductase

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; HYPOXIA; INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; UNITED STATES; VOMITING;

EID: 84859776781     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1779-5     Document Type: Article

References (23)

1. Jordan A, Reichard P (1998) Ribonucleotide reductases. Annu Rev Biochem 67:71-98 (Pubitemid 28411124)
2. Thelander L, Berg P (1986) Isolation and characterization of expressible cDNA clones encoding the M1 and M2 subunits of mouse ribonucleotide reductase. Mol Cell Biol 6:3433-3442
3. Eklund H, Uhlin U, Farnegardh M, Logan DT, Nordlund P (2001) Structure and function of the radical enzyme ribonucleotide reductase. Prog Biophys Mol Biol 77:177-268 (Pubitemid 34131599)
4. Thelander M, Graslund A, Thelander L (1985) Subunit M2 of mammalian ribonucleotide reductase. Characterization of a homogeneous protein isolated from M2-overproducing mouse cells. J Biol Chem 260:2737-2741 (Pubitemid 15139329)
5. Yen Y, Grill SP, Dutschman GE, Chang CN, Zhou BS, Cheng YC (1994) Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. Cancer Res 54:3686-3691 (Pubitemid 24241179)
6. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y (2000) A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404:42-49 (Pubitemid 30143125)
7. Guittet O, Hakansson P, Voevodskaya N, Fridd S, Graslund A, Arakawa H, Nakamura Y, Thelander L (2001) Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 276:40647-40651
8. Kunos CA, Chiu SM, Pink J, Kinsella TJ (2009) Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein. Radiat Res 172(6):666-676
9. Hreshchyshyn MM, Aron BS, Boronow RC, Franklin EW III, Shingleton HM, Blessing JA (1979) Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Int J Radiat Oncol Biol Phys 5:317-322 (Pubitemid 9155751)
10. Stehman FB, Bundy BN, Kucera PR, Deppe G, Reddy S, O'Connor DM (1997) Hydroxyurea, 5-fluorouracil infusion, and cisplatin adjunct to radiation therapy in cervical carcinoma: phase I-II trial of the Gynecologic Oncology Group. Gyn Oncol 66:262-267 (Pubitemid 27335415)
11. Rose P, Ali S, Watkins E, Thigpen J, Deppe G, Clark-Pearson D, Insalaco S (2007) Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: A Gynecologic Oncology Group Study. J Clin Oncol 25(19):2804-2810 (Pubitemid 47123190)
12. Feun L, Modiano M, Lee K, Mao J, Marini A, Savaraj N, Plezia P, Almassian B, Colacio E, Fischer J, MacDonald S (2002) Phase 1 and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chem Pharma 50(3):223-229 (Pubitemid 35013660)
13. Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M (2003) Phase 1 and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, administered for five days in patients with advanced solid tumors. Clin Cancer Res 9(11):4092-4100 (Pubitemid 37204025)
14. Yen Y, Margolin K, Doroshow J, Fishman M, Johnson B, Clairmont C, Sullivan D, Sznol M (2004) A phase I trial of 3-minopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol 54:331-342 (Pubitemid 39304428)
15. Kunos CA, Waggoner S, von Gruenigen V, Eldermire E, Pink J, Dowlati A, Kinsella TJ (2010) Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer. Clin Cancer Res 16(4):1298-1306
16. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
17. Kunos CA, Radivoyevitch T, Pink J, Chiu SM, Stefan T, Jacobberger J, Kinsella TJ (2010) Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers. Radiat Res 174(5):574-581
18. Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, Huang W, Eickhoff J, Erlichman C, Holen KD (2008) A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs 26(4):369-379
19. Knox JJ, Hotte SJ, Kollmannsberger C, Winquist E, Fisher B, Eisenhauer EA (2007) Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). Invest New Drugs 25(5):471-477 (Pubitemid 47222906)
20. Traynor AM, Lee JW, Bayer GK, Tate JM, Thomas SP, Mazurczak M, Graham DL, Kolesar JM, Schiller JH (2010) A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. Invest New Drugs 28(1):91-97
21. Duenas-Gonzalez A, Cetina-Perez L, Lopez-Graniel C, Gonzalez-Enciso A, Gomez-Gonzalez E, Rivera-Ruby L, Montalvo-Esquicel G, Munoz-Gonzalez D, Robles-Flores J, Vazquez-Govea E, De La Garza J, Mohar A (2005) Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: a randomized phase II study. Int J Radiat Oncol Biol Phys 61(3):817-823 (Pubitemid 40247977)
22. Hakansson P, Hofer A, Thelander L (2006) Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J Biol Chem 281:7834-7841 (Pubitemid 43847398)
23. Xue L, Zhou B, Liu X, Qiu W, Jin Z, Yen Y (2003) Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res 63(5):980-986 (Pubitemid 36278428)